Every material Form 8-K Roivant Sciences filed with the SEC in 2025, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
Roivant reported results for the quarter ended September 30, 2025. Net loss attributable to Roivant shareholders narrowed to $113.5 million from $230.2 million a year earlier, while revenue fell to $1.6 million from $4.5 million. R&D spending rose, and the company reported $4.4 billion in cash, cash equivalents, restricted cash and marketable securities.
Net loss attributable to Roivant was $113.5 million, or $0.17 per share, versus $230.2 million, or $0.31 per share, a year earlier
Revenue was $1.6 million versus $4.5 million in the prior-year quarter
R&D expenses rose to $164.6 million from $143.1 million; G&A expenses fell to $143.1 million from $202.9 million
Cash and marketable securities totaled $4.4 billion as of September 30, 2025; Investor Day is set for December 11, 2025
Roivant reported a loss from continuing operations of $273.9 million for the quarter ended June 30, 2025, compared with income of $31.6 million a year earlier, or $0.33 loss per share versus $0.01 income per share. Revenue fell to $2.2 million from $8.0 million, while research and development and general and administrative expenses rose, and share-based compensation increased sharply.
Revenue was $2.2 million versus $8.0 million in the prior-year quarter
Research and development expenses rose $32.4 million to $152.9 million; general and administrative expenses rose $34.1 million to $134.0 million
Share-based compensation in general and administrative expenses was $71.1 million versus $36.8 million
Cash, cash equivalents, restricted cash and marketable securities were $4.5 billion at June 30, 2025; a new $500 million buyback was approved in June 2025
Roivant reported a loss from continuing operations of $252.4 million for the three months ended March 31, 2025, compared with a $95.0 million loss a year earlier, on revenue of $7.6 million versus $9.0 million. For the fiscal year, it reported a $729.8 million loss from continuing operations, compared with income of approximately $4.5 billion in the prior year, which included a gain on the Telavant net assets sale. The company repurchased $1.3 billion of shares, cutting outstanding shares by 14%, and ended the period with $4.9 billion in cash, cash equivalents, restricted cash and marketable securities.
Q4 revenue was $7.6 million versus $9.0 million a year earlier; R&D expenses rose to $145.2 million from $107.6 million
Fiscal year loss from continuing operations of $729.8 million, compared with income of approximately $4.5 billion in fiscal 2024
Share repurchases of $1.3 billion as of March 31, 2025, reducing outstanding shares by 14% from March 31, 2024
Cash, cash equivalents, restricted cash and marketable securities of $4.9 billion at March 31, 2025
Roivant Sciences disclosed that its subsidiary, Roivant Sciences, Inc., signed a consulting agreement on March 16, 2025 with Rakhi Kumar, its former Chief Accounting Officer, who stepped down on February 20, 2025. Under the 18-month agreement, Ms. Kumar will provide advisory and transition services and may keep vesting in her outstanding equity awards, with any remaining unvested awards fully vesting at the end of the term if she meets her obligations. The filing is administrative and discloses no financial figures.
Consulting agreement dated March 16, 2025 with former Chief Accounting Officer Rakhi Kumar
Ms. Kumar stepped down effective February 20, 2025, as previously disclosed in a February 21, 2025 Form 8-K
Agreement runs 18 months and lets her continue vesting in outstanding equity incentive awards
Unvested awards fully vest at the end of the term if she complies with her separation obligations and the agreement is not terminated early
Roivant Sciences said Rakhi Kumar stepped down as Principal Accounting Officer and Chief Accounting Officer of its subsidiary Roivant Sciences, Inc., effective February 20, 2025. Jennifer Humes, a former JPMorgan Chase Managing Director, was appointed to both roles from the same date. The change affects the company's principal accounting officer, a role responsible for financial reporting, but the filing reports no financial results.
Rakhi Kumar stepped down effective February 20, 2025, and the company thanked her for her service.
Jennifer Humes was appointed Principal Accounting Officer and Chief Accounting Officer of RSI effective February 20, 2025.
Humes's offer letter includes a $380,000 base salary, a $190,000 target annual cash bonus, and a $261,500 sign-on bonus.
Equity grants have estimated values of approximately $1.2 million in RSUs and $800,000 in stock options, vesting over multiple years.
Roivant reported results for the quarter ended December 31, 2024. Revenue fell to $9.0 million from $15.6 million a year earlier, and the loss from continuing operations was $208.9 million, or $0.22 per share, compared with income of about $5.1 billion a year earlier, which included a one-time Telavant gain. Net income attributable to Roivant was $169.4 million, driven by a $327.0 million gain from discontinued operations tied to the sale of Dermavant to Organon.
Revenue, net was $9.0 million for the three months ended December 31, 2024, versus $15.6 million a year earlier.
R&D expenses rose $33.4 million to $141.6 million; G&A expenses rose $13.4 million to $141.5 million.
Income from discontinued operations was $327.0 million, reflecting the October 2024 sale of Dermavant to Organon.
Consolidated cash, cash equivalents, restricted cash and marketable securities were about $5.2 billion at December 31, 2024.
Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every Roivant Sciences filing is on SEC EDGAR ↗. 8-K briefs of other companies →